{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transduced+CD34%2B+Cells&page=3",
    "query": {
      "intervention": "Transduced CD34+ Cells",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 57,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transduced+CD34%2B+Cells&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Transduced+CD34%2B+Cells&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T06:34:17.069Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04140539",
      "title": "A Clinical Study to Enable Process Validation of Commercial Grade OTL-101",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Due to ADA Deficiency"
      ],
      "interventions": [
        {
          "name": "OTL-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "30 Days to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-10-15",
      "completion_date": "2021-08-30",
      "has_results": false,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04140539"
    },
    {
      "nct_id": "NCT01512888",
      "title": "Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Disease, X-linked"
      ],
      "interventions": [
        {
          "name": "CL20-i4-EF1α-hγc-OPT",
          "type": "GENETIC"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "CliniMacs",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "MALE",
        "summary": "Up to 24 Months · Male only"
      },
      "enrollment_count": 28,
      "start_date": "2016-08-17",
      "completion_date": "2039-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Memphis, Tennessee • Seattle, Washington",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01512888"
    },
    {
      "nct_id": "NCT00018018",
      "title": "Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "CD34+ cells transduced with ADA retrovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 8,
      "start_date": "2001-06-20",
      "completion_date": "2014-09-17",
      "has_results": false,
      "last_update_posted_date": "2019-12-12",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00018018"
    },
    {
      "nct_id": "NCT01734850",
      "title": "Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cal-1 modified HSPC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cal-1 modified CD4+ T lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Calimmune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-04",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2020-08-06",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • San Francisco, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01734850"
    },
    {
      "nct_id": "NCT04105166",
      "title": "Gene Therapy for Pyruvate Kinase Deficiency (PKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pyruvate Kinase Deficiency"
      ],
      "interventions": [
        {
          "name": "RP-L301",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rocket Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "8 Years to 50 Years"
      },
      "enrollment_count": 4,
      "start_date": "2020-07-06",
      "completion_date": "2025-06-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04105166"
    },
    {
      "nct_id": "NCT00272870",
      "title": "Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme (WHO Grade IV)",
        "Anaplastic Astrocytoma (WHO Grade III)"
      ],
      "interventions": [
        {
          "name": "06Benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "MGMT P140K",
          "type": "GENETIC"
        },
        {
          "name": "Meltenyi CliniMacs",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "DEVICE"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "5 Years to 55 Years"
      },
      "enrollment_count": 1,
      "start_date": "2005-12",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-08-29",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00272870"
    },
    {
      "nct_id": "NCT04091737",
      "title": "CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anemia, Sickle Cell"
      ],
      "interventions": [
        {
          "name": "Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-10-02",
      "completion_date": "2021-05-05",
      "has_results": false,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04091737"
    },
    {
      "nct_id": "NCT07476183",
      "title": "Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RPS19 Deficient Diamond-Blackfan Anemia"
      ],
      "interventions": [
        {
          "name": "APR-2020",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Apriligen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 4,
      "start_date": "2026-04-16",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 2,
      "location_summary": "Stanford, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07476183"
    },
    {
      "nct_id": "NCT01745120",
      "title": "A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "β-thalassemia Major"
      ],
      "interventions": [
        {
          "name": "LentiGlobin BB305 Drug Product",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 19,
      "start_date": "2013-08",
      "completion_date": "2018-02-21",
      "has_results": true,
      "last_update_posted_date": "2019-05-08",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Oakland, California • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01745120"
    },
    {
      "nct_id": "NCT04214886",
      "title": "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Acute Lymphoblastic Leukemia, Adult",
        "B-cell Lymphoma Refractory",
        "B-cell Lymphoma Recurrent"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "CD19-CD34 CAR transduced T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Loyola University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-12-31",
      "completion_date": "2034-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-08-15",
      "last_synced_at": "2026-11-17T06:34:17.069Z",
      "location_count": 1,
      "location_summary": "Maywood, Illinois",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214886"
    }
  ]
}